DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES

March 2022

Forward Looking Statements

This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic’s or our partners’ plans to develop and commercialize oral small-molecule integrin therapeutics and Morphic’s expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory approvals for MORF-057 and other candidates in development, the ability ofMORF-057 to treat inflammatory bowel diseases, including ulcerative colitis or Crohn’s disease, the ability of our platform to discover additional developable candidates (including against αvβ8 and αvβ1) or suitable indications (including in solid tumors or fibrotic diseases), the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations.

Statements including words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that may cause Morphic’s actual activities or results to differ significantly from those expressed in or implied by any forward-looking statement, including risks and uncertainties related to the forward-looking statements in this presentation and other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Morphic specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

2

Morphic: Leaders In Oral Integrin Therapies

Professor Tim Springer discovers integrin receptor class and highlights key role mediating many complex

diseases

Integrins Discovered

1990s

$4.6B in annual sales

4 approved inhibitors

All infused antibodies

Multiple failed attempts at oral integrin inhibitor

formulations

Springer Lab makes key discovery into integrin

receptor activity, catalyzes founding of Morphic to discover oral integrin

therapeutics based on unmatched structural

biology expertise

The FirstGeneration

2000s

The Next Generation

2015+

3

4

Morphic: Building Leadership in the Oral Integrin Space

Phase 2-ready oral program replicates blockbuster IBD antibody MoA

Proprietary ‘MInT’ Platform: unmatched capabilities for oral integrin drugs

Partnerships with marquee pharmaceutical companies

Broad pipeline addressing multiple major chronic disease areas

Strong cash position and seasoned management team

5

Unique Receptors: Unique Therapeutic Potential

• Only receptor to signal bidirectionally, giving them central biologic roles in complex diseases: autoimmune, fibrotic, cardio-metabolic and cancer

• Expensive, complex biologics have shown blockbuster efficacy in targeting integrins

What are integrins?

Extracellular matrix

Cytoskeleton

Inflammatorybowel

diseaseSolid

tumors

Fibrotic diseases

Now Morphic has built the platform to deliver the advantages of oral small molecule drugs to integrin targeting, with an initial focus on three major areas.

MInT: The Only Integrated Oral Integrin Platform

Unmatched structural biology expertise creates the foundation for leadership in small molecule integrin inhibitors

Know-how and development processes continually optimizing to add value and accelerate each new development program. Exclusive license with Schrodinger enables drug binding and proprietary optimization

Proprietary integrin-specific assay suite and highly informative models

Proprietary integrin structure

determination

Tunable product candidate engine

Deep integrin-specific translation

capabilities

Targeted approach to disease areas

with unmet need

Focus on indications where integrin modulation can have major therapeutic impact over standard of care, e.g. IBD, fibrotic disease and cancer

6

Status

Target (Program) Indication Preclinical Phase 1 Phase 2

α4β7 (MORF-057) IBD: UC & Crohn’s Disease

Next-generation α4β7

selective inhibitorsAdditional potential GI indications: EGIDs, pouchitis, etc.

αvβ8 Solid tumors

Undisclosed target Pulmonary arterial hypertension

Undisclosed targets Multiple indications

Morphic: A Deep Proprietary & Partnered Pipeline

Proprietary Pipeline

7

Partnered Programs

• $100 million upfront, $20 million option fee paid

• Undisclosed targets including antibody agonists of an integrin

MORF-057• Small molecule inhibitor of α4β7 – a well-

validated mechanism to treat IBD

• Positive phase 1 data highly supportive of rapid clinical progression

8

Indications

MORF-057: First-In-Class Oral Integrin Drug for IBD

9

Highly selective orally available small molecule inhibitor of α4β7,

well validated mechanism for the treatment of IBD through

approved monoclonal antibody vedolizumab

Candidate: MORF-057Occluding α4β7 blocks intestinal homing of

lymphocytes, which in turn reduces pathologic inflammation in IBD

Inflammatory bowel disease with initial focus on ulcerative

colitis

Approximately 1.6 million Americans currently have irritable bowel disease 1

Mechanism Clinical ProgramWell tolerated across 3 phase 1 trials, dose dependent and consistent PK,

α4β7 receptor saturation at 100 mg BID

No quantifiable levels of α4β1 RO observed

Phase 2 program beginning 1Q22 with open-label phase 2a, randomized controlled phase 2b trial to follow1Chrohn's and Colitis Foundation of America

α4β7 Inhibition is a Proven Mechanism to Treat IBD

Approved antibody Entyvio®(vedolizumab)

Sub-endothelial space - gut

Vascular space - blood

T-cell

a4b7

MAdCAM-1Endothelial cell

• Vedolizumab, an anti-α4β7 antibody, inhibits T-cell trafficking via well validated mechanism to treat UC and Crohn’s disease

• Since approval, >150,000 patients have received vedolizumab 1

• Vedolizumab generated $4Bsales in FY202

1Takeda press release2Global DataENTYVIO® is a registered trademark of Millennium Pharmaceuticals, Inc. 10

Phase 1 Program with Biomarkers Complete

1. SAD cohort: safety, tolerability, and PK/PD 2. Food Effect Cohort to determine PK of a single, projected clinically relevant dose3. MAD cohort: safety, tolerability, and PK/PD, including receptor occupancy data and inflammatory biomarkers two weeks BID dosing

Three-part Phase 1 Design:

Phase 1: SAD*

Phase 1: Food-effect

Phase 1: MAD**

Phase 2

5 cohorts; 6-8 HVs/cohort

2 cohorts; 4-6 HVs/cohort

3 cohorts; 6-8 HVs/cohort

Ph1 Trial Design

Format: Randomized, double-blind, placebo-controlled trialPopulation: HealthyvolunteersEndpoints: Safety, PK and PD Dosing: Single and multiple dose of MORF-057

11

*SAD: single ascending dose**MAD: multiple ascending dose

2022

Phase 2a: Open label (UC)Phase 2b: Randomized control trial (UC)

Phase 1 Overview: Data Exceed Pre-defined Targets

12

MORF-057 very well-tolerated in three phase 1 studies: SAD, MAD and food effect

PD profile demonstrated clear dose and time dependent α4β7 receptor occupancy and complete α4β7 saturation observed

Predictable PK profile with excellent serum exposures - at lower-than-expected doses

Clear rationale to rapidly advance MORF-057 toward approval in ulcerative colitis

MORF-057 Saturates the α4β7 Receptor in a Time and Dose Dependent Fashion

13

MORF-057 achieved >95% mean receptor occupancy (RO) of the α4β7 integrin at three highest dose levels and demonstrated ability to saturate α4β7 receptor in individual subjects in dose cohorts above 25 mg

α4β7 RO vs. MORF-057 Plasma Concentration and Dose

25 50 100 150 400

0

20

40

60

80

100

Dose (mg)

abR

O

1 7 14 1 7 14 1 7 14

0

20

40

60

80

100

Day

a4b

7 R

O (

%)

25 mg BID50 mg BID100 mg BID

SAD MAD

Ray, et al, ECCO 2021

MORF-057 Pharmacokinetics are Dose-Dependent and Predictable

14

0 4 8

12

144

216

288

312

316

320

324

1

10

100

1000

Time From the First Dose (hr)

Concentr

ation (

ng/m

L)

50 mg BID100 mg BID

25 mg BID

Mean Plasma Concentration of MORF-057/Time

Ray, et al, ECCO 2021

MORF-057 Achieves >90% RO at 8ng/ML

15

α4β7 RO vs. MORF-057 Plasma Concentration and Dose

1 10 1000

20

40

60

80

100

5000.5

Concentration (ng/mL)

a4b

7 R

O (

%) SAD 100 mg 12 hr

SAD 150 mg 12 hr

SAD 400 mg 12 hr

SAD 25 mg 12 hr

MAD 50 mg BID D1

MAD 100 mg BID D1

MAD 25 mg BID D1

SAD 50 mg 12 hr

SAD 400 mg 36 hr

MAD 50 mg BID D14

MAD 100 mg BID D7MAD 100 mg BID D14

MAD 25 mg BID D7MAD 25 mg BID D14

1 Veny et al 2021

Changes in Lymphocyte Subsets Consistent with Activity of Approved Mabs Inhibiting α4β7

16

Changes in lymphocyte migration patterns are correlated with reduced inflammation in other IBD therapeutics including vedolizumab1

P M P M P M P M

0

100

200

300

% o

f b

as

eli

ne

p=0.1508✱

p=0.0317p=0.6905

✱p=0.0317

β7hi effector

memory T cells

β7+ central

memory T cells

β7+

naive T cells

β7hi CD3-CD4-

lymphocytes

P M

0

1

2

3

CC

R9 E

xp

ressio

n

(Rela

tiv

e t

o P

red

os

e)

✱p= 0.0238

CCR9 mRNAExpression in Blood

Statistically Significant Changes in Key Pharmacodynamic Biomarkers2

• β7 high = expressing high levels of integrin β7

• β7+ = expressing β7• P =placebo• M =MORF-057; D=

day• CCR9 = inflammatory

marker

1 Veny et al, J. Crohn’s and Colitis, 2021, 441–4522Ray, et al, ECCO 2021

*statistically significant

17

Statistically Significant Changes in Pharmacodynamic Biomarkers

Predose D1 D7 D14

80

90

100

110

120

β7+ Central memory T cells

p=0.0317vs Placebo

*

PLACEBO

100 mg BID

50 mg BID

25 mg BID

Predose D1 D7 D14

80

90

100

110

120

β7 high Effector memory T cells

Med

ian

%o

f b

aselin

e p=0.0303vs Placebo

*

Changes in Lymphocyte Subsets are Consistent with Activity of Approved Mabs Inhibiting α4β7

Ray, et al, ECCO 2021

MORF-057 Phase 2 Clinical Program

Phase 2a

18

2022

Open label (UC)

Phase 2b Randomized control trial (UC)

Provide rapid proof of concept for MORF-057 as an α4β7 inhibitor comparable or superior to vedolizumab in patients suffering from UC

• Open label (n=35)

• 100mg BID MORF-057

• Primary endpoint: Robarts Histopathologic Index (RHI)

• Deep translational data set to inform on MOA and predictive biomarkers

Phase 2a

• Double-blind, placebo-controlled, randomized trial

• Dose ranging efficacy and safety to inform Phase 3 design

Phase 2b Randomized Controlled Trial

2023

EMERGINGPIPELINECreating the next generation of proprietary integrin inhibitor candidates

19

αvβ8 Small Molecule Integrin Inhibitor Immuno-oncology Program

20

Small molecule inhibitors of the αvβ8 integrin in preclinical

development

Αvβ8 Programαvβ8 inhibition suppresses

activation of TGFβ isoforms 1 and 3

IndicationsSolid tumors, which make up

approximately 90% of all adult human cancers

Mechanism DataOral inhibitor αvβ8 integrin , in

combination with anti-PD-1, drives efficacy across mouse models of

treatment-resistant breast cancer including the EMT6 and PyMT

syngeneic breast cancer models

αvβ8 Small Molecule Inhibitor Enhances Checkpoint Inhibitor Response in Immune Refractory Model

αvβ8 inhibition blocks activation of TGF-b, a key regulator of tumor formation, progression, and metastasis

21

EMT6 Murine Breast Cancer Model

EMT-6 inoculation on day 0. Dosing window days 6 through 27

Preclinical Data from Oral αvβ8 Program Demonstrate Potent Anti-Tumor Response Through TGFβ Pathway

In combination with checkpoint inhibitor, αvβ8 integrin inhibitor demonstrated potent anti-tumor activity efficacy in checkpoint-resistant models of breast cancer and induced a lasting

anti tumor effect

22

8 i h + i i h i

i i

i

i i

h g

i +

+ +i

+ + 8

Deep Specialist Expertise Across Management, and Board of Directors

23

PRAVEEN TIPIRNENI, MDPresident and

Chief Executive Officer

BRUCE ROGERS, PhD

Chief Scientific Officer

MARC SCHEGERIN, MD

Chief Financial OfficerChief Operating Officer

Gustav Christensen, MBA Chairman Morphic Board, former CEO, Dyax

Timothy Springer, PhD Founder, Morphic Therapeutic, Member of Morphic Scientific Advisory Board; Latham Family Professor, Professor of Biological Chemistry and Molecular Pharmacology; Professor of Medicine, Harvard Medical School

Norbert Bischofberger, PhD President & CEO, Kronos; EVP R&D, CSO, Gilead

Martin Edwards, MD Chairman, Kalvista; Senior Partner, Novo Holdings

Nisha Nanda, PhD Chief Development officer, Loxo at Lilly

Amir Nashat, PhD Managing Partner, Polaris Partners

Susannah Gray, PhD Former CFO, Royalty Pharma

Joseph P. Slattery, CPA Former CFO, Transenterix, Baxano, Digene

Praveen Tipirneni, MD President and CEO Morphic Therapeutic

BOARD OF DIRECTORS

WILLIAM DEVAULGeneral Counsel and Secretary

Morphic: Building Leadership in the Oral Integrin Space

24

Phase 2-ready oral program replicates blockbuster IBD antibody MoA

Proprietary ‘MInT’ Platform: unmatched capabilities for oral integrin drugs

Partnerships with marquee pharmaceutical companies

Broad pipeline addressing multiple major chronic disease areas

Strong cash position and seasoned management team

DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES

APPENDIX

26

Morphic: A New Chapter In Integrin History

27

1990 2000 2010Heavy Big Pharma Investment

Phase III failures for oral drugs

Drug withdrawal

Heavy Springer Lab Investment2015

Springer discoversintegrins

Morphic founded on Springer IP for oral integrin drug design

Entyvio® approved

3 non-oral approvals

2021

Morphic oral candidates enter clinic

2020

MORF-057 PoC

Integrins: Conformation is Key to Function

28

• Integrins shift between an open and closed conformation

• Morphic develops ig k “h h ” i g i f i i

• Previous oral integrin inhibitors locked conformation in a “diseased” active state, leading to clinical failures

• This was a key discovery of the Springer Lab that led to the first small molecules targeting conformational change, and the formation of Morphic

Closed Open

Morphic Integrin Technology (MInT) Platform

29

Tunable Product Candidate Design Engine

• Unique and well characterized library of integrin small molecules

• Exclusive Schrödinger Computational Chemistry Collaboration

• In Vitro Integrin Assay Panels

Biology and Disease Translation Capability

• Proprietary assay design

• Building a deep understanding of integrin biology in human diseases

• sophisticated and comprehensive suite of in vitro, ex vivo, and disease-specific in vivo assay

Proprietary Integrin Structure Determination

• World-leading integrin structure capabilities

• Insights initiated at Springer Laboratory

• >300 Crystallized Integrin Structures

Morphic has already delivered accelerated discovery work by leveraging insights from early programs: each iteration augments our chemistry and biology knowledge.

MORF-057 Has Inherently High Selectivity for α4β7 Versus Other Integrins

30

α4β7

MAdCAM-1

α4β1

Endothelial cell

Leukocyte

Inhibiting VCAM-1

brings risk of PML

VCAM-1• MORF-057 is highly selective for α4β7 over α4β1 in cell

adhesion assays in 50% human serum (over 3 orders of magnitude)

• MORF-057 was designed to be a potent and selective oral inhibitor of the integrin α4β7 and not α4β1, a related integrin

MORF-057

Inhibitorα4β7 IC50

a

RPMI8866 MAdCAM in 50% serum

α4β7/α4β1

Fold selectivity

MORF-057 1.2 nM >3,000

Vedolizumab 0.035 nM >3,000

Natalizumab 0.166 nM 1-12

AJM300 93 nM 8-45

Etrolizumab 0.019 >106

a Cell line characteristics: Jurkat cells have been traditionally used for specifically assessing α4β1 potency, as these cells do not express α4β7. RPMI8866 cells have lower levels of α4β1 that likely better approximate expression levels in human blood. DDW 2020, Morphic Therapeutic, Jamie Wong, ePoster Tu1283

MORF-057: Key Preclinical Data

31

RO NHP data

Chronic toxRO measured at Ctrough

in non-human primates dosed with selective α4β7

inhibitor, MR-5288, a tool compound related to MORF-057

In mouse gut homing assay, MORF-057 inhibits T Cell homing with equivalent potency as an α4β7 antibody

B.)The performance of the RO assay for α4β7 (A) and α4β1 (B) is similar between NHV and UC patients. Data are ± SD

A.)

MORF-057

Cell surface α4β7

Fluorescently labeled MAdCAM-based probe that competes with MORF-057

No signal, fully occupied

RO Analysis

MORF-057 Well tolerated Across Phase 1

32